Tadalafil
Product Images NDC 70934-473

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70934-473). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

70934 473 06 Master Bottle Label Approval Rev A 12 19

Packaging label for Tadalafil tablets, USP 20 mg by Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label indicates a package containing 6 tablets for prescription use. Storage instructions include controlled room temperature and protection from children, with specific dosage and handling notes.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 01

Chemical structure of tadalafil, illustrating its molecular framework with fused rings and functional groups. The image depicts the arrangement of carbon, nitrogen, oxygen, and hydrogen atoms in the compound.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 02

Four line graphs displaying blood pressure changes over time comparing Tadalafil to placebo. The plots show differences in standing systolic and diastolic BP, and supine systolic and diastolic BP across a 0 to 96-hour timeframe, with error bars indicating variability.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 03

Two line graphs showing changes in systolic blood pressure over 24 hours post-dose. The top graph displays standing systolic BP, and the bottom graph displays supine systolic BP. Both compare Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg, with blood pressure measured in mmHg over time in hours.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 04

A line graph depicting the change in systolic blood pressure (mmHg) over a 12-hour period following administration of tadalafil or placebo combined with 8 mg doxazosin once daily. The graph compares four conditions: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00, all with 8 mg doxazosin at 08:00. Data points show variations in systolic blood pressure over time.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 05

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing conditions: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days of administration. The graph includes data points with error bars to indicate variability.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 06

A line graph comparing the change from baseline in the IPSS total score over 12 weeks between Tadalafil 5 mg and placebo treatments. The x-axis represents the duration of treatment in weeks, and the y-axis shows the change in score. Tadalafil shows a greater reduction in score over time compared to placebo.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 07

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment with Tadalafil 5 mg versus placebo. The x-axis shows duration of treatment in weeks, and the y-axis shows change in IPSS score, with statistically significant differences noted at certain points.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 08

A line graph comparing the least-squares mean change from baseline over 26 weeks of therapy between Tadalafil/Finasteride and Placebo/Finasteride groups. The graph shows data points at 0, 4, 12, and 26 weeks, with annotations indicating statistical significance at various time points.*

FDA Label Image

84125597 9492 4bb8 Bbba 6d56a874e856 09

A line graph showing the change from baseline in IPSS Total Score over a 12-week duration for two groups: Tadalafil 5 mg and placebo. The graph indicates a greater reduction in score for Tadalafil 5 mg compared to placebo over time, with statistical significance indicated at week 12 (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.